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ABSTRACT
Introduction: Latanoprostene bunod (LBN) is a
novel nitric oxide (NO)-donating prostaglandin
F2a analog. We evaluated the long-term safety
and intraocular pressure (IOP)-lowering efficacy
of LBN ophthalmic solution 0.024% over 1 year
in Japanese subjects with open-angle glaucoma
(OAG) or ocular hypertension (OHT).
Methods: This was a single-arm, multicenter,
open-label, clinical study. Subjects aged 20 years
and older with a diagnosis of OAG or OHT
instilled 1 drop of LBN ophthalmic solution
0.024% in the affected eye(s) once daily in the
evening for 52 weeks and were evaluated every
4 weeks. Safety assessments included vital signs,
comprehensive ophthalmic exams, and
treatment-emergent adverse events (AEs).
Absolute and percent reductions from baseline
in IOP were also determined.
Results: Of 130 subjects enrolled, 121 (93.1%)
completed the study. Mean age was 62.5 years,
and mean (standard deviation) baseline IOP was
19.6 (2.9) and 18.7 (2.6) mmHg in study eyes
and treated fellow eyes, respectively. Overall,
76/130 (58.5%) and 78/126 (61.9%) subjects
experienced C1 AEs in study eyes and treated
fellow eyes, respectively. In both study eyes and
treated fellow eyes, the most common AEs were
conjunctival hyperemia, growth of eyelashes,
eye irritation, and eye pain. At 52 weeks, 9% of
treated eyes had an increase in iris
pigmentation compared with baseline based
on iris photographs. No safety concerns
emerged based on vital signs or other ocular
assessments. Mean reductions from baseline in
IOP of 22.0% and 19.5% were achieved by week
4 in study and treated fellow eyes, respectively.
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These reductions were maintained through
week 52 (P\0.001 vs. baseline at all visits).
Conclusion: Once daily LBN ophthalmic
solution 0.024% was safe and well-tolerated in
Japanese subjects with OAG or OHT when used
for up to 1 year. Long-term treatment with LBN
ophthalmic solution 0.024% provided
significant and sustained IOP reduction.
Trial registration: ClinicalTrials.gov identifier,
NCT01895972.
Funding: Bausch & Lomb, Inc. a division of
Valeant Pharmaceuticals International Inc.
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INTRODUCTION
Open-angle glaucoma (OAG) is associated with
progressive visual field damage and visual
function loss that can lead to disability and
adversely affect health-related quality of life
[1–4]. Ocular hypertension (OHT) is considered
a key risk factor for primary OAG, and reducing
intraocular pressure (IOP) and maintaining
target IOP can delay or prevent the onset of
primary OAG in patients with OHT and slow
disease progression in patients with glaucoma
[5–10]. Accordingly, recommended goals of
treatment for patients with OAG and those
with OHT at risk of developing OAG include
maintaining IOP within a target range and
achieving stability of the optic nerve/retinal
nerve fiber layer status and of visual fields
[11, 12]. A desirable IOP range should be
determined for each patient based on a goal of
minimizing the impact of visual field loss on
quality of life; the upper limit of this range is
considered the ‘‘target pressure’’ for achieving
the sought after clinical goals. Lowering of IOP
by 25% is a well-documented benchmark for
slowing the progression of primary OAG, but
even more aggressive targets may be appropriate
in some patients depending on disease severity
and other risk factors [11–13].
Topical prostaglandin analogs are potent
ocular hypotensive agents with good
IOP-lowering efficacy and a favorable safety
profile [14, 15]. Common ocular side effects of
topical prostaglandin receptor agonists include
conjunctival hyperemia, elongation and
darkening of eyelashes, iris pigmentation
changes, and periocular skin hyper-
pigmentation [16–19]. While these agents are
considered first-line interventions for
pharmaceutical lowering of IOP in OAG and
OHT, it is not uncommon for patients to require
add-on therapy to reach target IOP [20].
Latanoprostene bunod (LBN; BOL-303259-X,
Bausch & Lomb, Inc.) is a novel IOP-lowering
compound with a dual mechanism of action.
Following ocular instillation, LBN is rapidly
metabolized into latanoprost acid, a
prostaglandin F2a analog, and butanediol
mononitrate, a nitric oxide (NO)-donating
moiety, which is subsequently reduced to 1,4
butanediol, an inactive metabolite, and NO
(Fig. 1) [21, 22]. Latanoprost reduces IOP
primarily by increasing uveoscleral outflow via
long-term remodeling of the extracellular
matrices in the ciliary body (‘‘non-
conventional outflow’’) [23–28], whereas NO
donors appear to induce relaxation of the
trabecular meshwork and Schlemm’s canal
leading to increased aqueous outflow
(‘‘conventional outflow’’) [29, 30]. Preclinical
and clinical studies suggest that both active
moieties of LBN (latanoprost acid and NO)
contribute to its potent IOP-lowering effect
[21, 22, 29]. In animal models of OHT or
glaucoma, LBN produced significantly greater
reductions in IOP than equimolar
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concentrations of latanoprost [21]. In a study
using prostanoid FP-receptor knockout mice,
LBN administration lowered IOP from 0.45 to
1.23 mmHg, while latanoprost had no effect,
providing evidence to support a distinct
pharmacologic activity of NO [31]. Clinically,
LBN 0.024% was shown to have a greater
IOP-lowering effect compared with latanoprost
0.005% in a phase 2, randomized,
investigator-masked, parallel-group dose-
ranging study in 413 patients with OAG
or OHT (the VOYAGER study [22];
ClinicalTrials.gov identifier, NCT01223378).
Furthermore, a study comparing the effects of
LBN and latanoprost on human trabecular
meshwork cell (HTMC) contractility showed
that LBN produces significantly greater HTMC
relaxation than latanoprost suggesting that
increased conventional outflow facility may
contribute to the additional IOP-lowering effects
of LBN compared with latanoprost [21, 29].
A previous single-center, open-label clinical
study in healthy Japanese male volunteers (the
KRONUS study [32]; ClinicalTrials.gov
identifier, NCT01895985) demonstrated that
LBN 0.024% administered once daily (QD) in
the evening significantly lowered IOP
throughout the day in this population. The
current study was designed to evaluate the
clinical safety of LBN ophthalmic solution
0.024% (hereafter referred to as LBN 0.024%)
over a 1-year treatment period in a Japanese
population with OAG or OHT. The ability of
LBN 0.024% to maintain lowered IOP over this
time frame was also evaluated.
METHODS
Study Design
The JUPITER study (ClinicalTrials.gov
identifier, NCT01895972) was a single-arm,
open-label, clinical study conducted at 12
investigational sites in Japan between July 5,
2013 and April 2, 2015. The protocol was
approved by the Institutional Review Board
at each site prior to the initiation of the
study. The study was conducted in
accordance with Good Clinical Practice, as
described in the International Conference on
Harmonisation Harmonized Tripartite
Guidelines for Good Clinical Practice; the
United States Code of Federal Regulations;
and the ethical principles in the Declaration
of Helsinki. All subjects provided written
informed consent before any study-specific
procedures were performed. Eligible subjects
instilled LBN 0.024% QD in the evening
(approximately 8 PM) for 52 weeks and were
evaluated every 4 weeks.
Fig. 1 Metabolism of latanoprostene bunod to latano-
prost acid (1) and butanediol mononitrate with subse-
quent release of nitric oxide (2) and 1,4-butanediol, an
inactive metabolite
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Subjects
The study enrolled males and females,
C20 years of age, with a diagnosis of OAG
(including normal-tension glaucoma [NTG],
pigmentary, or pseudoexfoliative glaucoma),
or OHT in one or both eyes. Eligible subjects
were required to have a mean/median IOP
C15 mmHg and B36 mmHg at 10 AM in at
least 1 eye, and IOP B36 mmHg in both eyes at
Visit 3 (Day 0/baseline), which occurred after a
washout period in those subjects on topical
hypotensive treatment at the time of
enrollment. Eligible subjects also must have
had corrected decimal visual acuity (VA) or
best-corrected decimal visual acuity (BCVA)
C0.5 in both eyes and central corneal
thickness B600 lm.
Subjects were ineligible for study
participation if they had participated in
another clinical trial within 30 days of Visit 3,
or within 30 days of Visit 1 (screening) for
subjects requiring a washout period; had a
known hypersensitivity or contraindication to
any of the ingredients of the study treatments;
were unable to discontinue contact lens use or
other eye drop mediations (e.g., artificial tears)
during and 15 min after instillation of study
drug and during study visits; had any condition
that prevented reliable applanation tonometry;
had advanced glaucoma (mean deviation
\-12 dB or split fixation) or other significant
ophthalmic disease; or had very narrow angles
(three quadrants with less than Grade 2), a
history of or current angle closure, or congenital
or secondary glaucoma. The study also excluded
subjects who required treatment with ocular or
systemic corticosteroids, or were in need of or
expected to require additional topical or
systemic treatment for OAG or OHT, or
subjects with an anticipated need to initiate or
modify medication known to affect IOP (e.g.,
b-adrenergic antagonists, a-adrenergic agonists,
calcium channel blockers, angiotensin-
converting enzyme inhibitors, and angiotensin
II receptor blockers) during the study.
Study Treatments and Assessments
Baseline data were recorded at Visit 1. Subjects
undergoing treatment with an IOP-lowering
medication were required to undergo a
washout period, with the length of the
washout dependent on the type of
medication used (a minimum of 5 days for
miotics and oral/topical carbonic anhydrase
inhibitors, 14 days for sympathomimetics, and
28 days for topical prostaglandin analogs,
b-blockers, and combination drugs with
b-blockers). A mid-washout visit (Visit 2) was
scheduled for those requiring washout longer
than 2 weeks. Any subject with a mean/median
IOP exceeding 36 mmHg in either eye at any
point during the washout period was
withdrawn from the study.
All subjects were assigned to treatment with
LBN ophthalmic solution 0.024% QD. Each
subject was instructed to instill one drop in
the affected eye(s) QD in the evening
(approximately 8 PM) beginning in the evening
of Visit 3 and continuing to the evening before
Visit 16 (week 52). The study eye was the eye
that qualified per inclusion criteria at Visit 3. If
both eyes qualified, then the study eye was the
eye with the higher IOP at Visit 3, or the right
eye if both eyes had the same IOP. If both eyes
of a subject had a diagnosis of OAG or OHT,
then both eyes were treated for the duration of
the study, even if only one eye qualified at
baseline. After the baseline visit, subjects
completed a total of 13 visits, with visits
occurring every 4 weeks from Visit 4 (week
4 ± 3 days) through Visit 16 (week
52 ± 7 days). A diary card for recording LBN
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administration was dispensed at baseline and
collected at the last study visit.
Safety assessments included treatment-
emergent adverse events (AEs), vital signs,
corrected decimal VA, conjunctival hyperemia
assessment, slit-lamp examination findings,
ophthalmoscopy findings, photographs of the
irides, eyelids, and eyelashes, visual field
assessment, gonioscopy, and pachymetry. VA
was measured at baseline and all study visits
using a decimal VA chart. The investigator
graded conjunctival hyperemia prior to
slit-lamp examination and IOP measurement
on a scale of 1–4 using photographic standards
(1 = none, 4 = severe). Photographs were taken
using a slit-lamp mounted digital camera at
Visits 3 (Day 0) and 16 (week 52), and were
evaluated at the end of the study to assess any
changes. Iris pigmentation was graded using
four categories (1 = no increase, 2 = undecided,
3 = possible increase, and 4 = clear increase) by
an independent reviewer, whereas any change
in eyelid pigmentation or eyelashes was
evaluated by the investigator and reported as
an AE.
IOP was assessed at screening, the
mid-washout visit (if applicable), baseline, and
at each post-baseline study visit in both eyes at
10 AM ± 30 min using a Goldman applanation
tonometer. For each patient, IOP was measured
by the same operator using the same tonometer
at each visit whenever possible.
Endpoints
Efficacy endpoints were absolute IOP values and
reduction from baseline (RFB) in IOP. Safety
endpoints included AEs, vital signs, corrected
decimal VA, conjunctival hyperemia
assessment, slit-lamp examination,
ophthalmoscopy, photographs, visual field
assessment, gonioscopy, and pachymetry.
Statistical Analysis
The sample size of 130 subjects was not based
on power considerations for testing any
hypothesis and was assumed to provide
sufficient data to study the safety profile of
LBN 0.024% QD over 52 weeks using descriptive
statistics.
Treatment adherence was defined as the
percentage of prescribed instillations received
(based on diary card entries).
Safety analyses were based on the safety
population, which included all subjects who
received at least one dose of study drug.
Treatment-emergent AEs were coded using
Medical Dictionary for Regulatory Activities,
version 16.0 and summarized by severity and
relationship to study drug. Treatment-emergent
ocular AEs were summarized for study eyes and
treated fellow eyes, and treatment-emergent
non-ocular AEs were summarized at the
subject level by system organ class and
preferred term.
Vital sign measurements and visual acuity
were summarized using descriptive statistics.
Conjunctival hyperemia was categorized as
none, mild, moderate, and severe, with the
number and percentage of subjects in each
category presented by visit. The number and
percentage of subjects having C1 hyperemia
and C1 moderate or severe hyperemia were also
presented by visit. Iris photographs from Visits
3 and 16 were evaluated for pigmentation
changes. A subject was identified as having a
possible or clear increase in iris pigmentation
for a given eye if baseline/post-baseline
photograph pairs had a final pair grade of 3 or 4.
Efficacy analyses were based on the safety
population (all subjects who received at least 1
dose of study drug). The absolute IOP, RFB in
IOP, and mean percent change from week 4
through week 52 were summarized for study
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eyes and treated fellow eyes at each visit using
descriptive statistics and discrete summaries
(proportion of subjects with RFB in IOP C5
and C10 mmHg; proportion of subjects with
RFB in IOP at each visit categorized into: B-5,
-4 to 0, 1–4, 5–9, 10–14, and C15 mmHg). In
addition, a paired t test was performed on the
RFB at each visit.
In general, continuous variables were
summarized by sample size, mean, standard
deviation (SD), median, minimum, and
maximum. Summaries for discrete variables
included the tabulation of frequencies and
percentages. All statistical analyses were
performed using the SAS software (SAS
Institute, Cary, NC, USA) version 9.2 or higher.
RESULTS
Subjects
A total of 151 subjects were screened. Of these,
130 subjects were enrolled and 121 (93.1%)
completed the study. Reasons for study
discontinuation included AEs (n = 4),
withdrawal of consent (n = 4), and investigator
decision (n = 1).
The mean (SD) age of the study population
was 62.5 (18.9) years (range 39–81 years); the
median age was 64.0 years. A slightly higher
percentage of subjects was female than male
(56.9% vs. 43.1%), and all subjects were
Japanese. The majority of subjects (90.0%)
were on prior IOP-lowering medication at
screening and required a washout. In all but
four subjects, both eyes qualified for treatment.
Hence, 130 study eyes and 126 fellow eyes
qualified for treatment. Mean [SD] corneal
thickness at baseline was similar between
study eyes (546.1 [31.2] lm) and treated fellow
eyes (544.4 [31.1] lm). Mean (SD) baseline IOP
was 19.6 (2.9) mmHg (range 15.0–30.0 mmHg)
for study eyes and 18.7 (2.6) mmHg (range
14.5–27.0 mmHg) for treated fellow eyes. The
majority of study eyes (74.6%) and treated
fellow eyes (85.7%) and all non-treated fellow
eyes had a baseline IOP within 15–21 mmHg;
baseline IOP was between 22 and 29 mmHg in
24.6% of study eyes and 14.3% of treated fellow
eyes. One study eye had a baseline IOP between
30 and 36 mmHg. All eyes had brown iris color.
The mean (SD) duration of exposure to LBN
ophthalmic solution 0.024% was 351.5 (59.30)
days, and the median (range) duration of
exposure was 364.0 (28–371) days. Based on
diaries, compliance with dosing instructions
was excellent (81–120% for all subjects).
Safety
At least 1 ocular AE was reported for 76 (58.5%)
study eyes and 78 (61.9%) treated fellow eyes
(Table 1). Ocular AEs considered
treatment-related were reported in a similar
percentage (48%) of study eyes and treated
fellow eyes. The most frequently reported
ocular AEs in study eyes and treated fellow
eyes were conjunctival hyperemia (17.7% and
16.7%, respectively), growth of eyelashes
(16.2% and 16.7%), eye irritation (11.5% and
11.9%), and eye pain (10.0% and 10.3%).
Ocular AEs were considered mild to moderate
in severity; no severe ocular AEs were reported.
There were four study discontinuations
secondary to AEs, including three subjects
with serious AEs (malignant lung neoplasm,
lung adenocarcinoma, and gastric cancer), and
one subject who experienced a non-serious AE
of cataract in the treated fellow eye, none of
which were considered related to study
treatment.
Overall, 67 (51.5%) subjects experienced at
least 1 non-ocular AE. The most commonly
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reported non-ocular AEs included
nasopharyngitis (42 [32.3%] subjects),
influenza (5 [3.8%] subjects), eczema (4 [3.1%]
subjects), and osteoporosis (3 [2.3%] subjects).
All other non-ocular AEs occurred in one or two
subjects each. None of the non-ocular AEs were
considered related to study drug.
Eight subjects experienced ten non-ocular
serious AEs (road traffic accident, fibula fracture,
and tibia fracture [all in one subject]; breast
cancer; lung adenocarcinoma; large intestine
polyp; gallbladder stones; malignant lung
neoplasm; gastric cancer; and vestibular
neuronitis), three of which (gallbladder stones,
Table 1 Incidence of ocular treatment-emergent adverse events occurring in at least 1% of subjects in the study eye or the
treated fellow eye (safety population)
Adverse events LBN 0.024%
Study eye
(N5 130) n (%)
Treated fellow eye
(N5 126) n (%)
C1 ocular AE 76 (58.5) 78 (61.9)
C1 treatment-related ocular AE 62 (47.7) 61 (48.4)
Eye disorders
Conjunctival hyperemiaa 23 (17.7) 21 (16.7)
Growth of eyelashes 21 (16.2) 21 (16.7)
Eye irritation 15 (11.5) 15 (11.9)
Eye pain 13 (10.0) 13 (10.3)
Iris hyperpigmentation 5 (3.8) 5 (4.0)
Blepharal pigmentation 4 (3.1) 4 (3.2)
Blepharitis 3 (2.3) 3 (2.4)
Eye pruritus 3 (2.3) 3 (2.4)
Asthenopia 3 (2.3) 2 (1.6)
Conjunctival hemorrhage 2 (1.5) 3 (2.4)
Punctate keratitis 3 (2.3) 2 (1.6)
Trichiasis 3 (2.3) 2 (1.6)
Cataract 1 (0.8) 3 (2.4)
Hordeolum 1 (0.8) 3 (2.4)
Foreign body sensation in eyes 2 (1.5) 1 (0.8)
Visual impairment 1 (0.8) 2 (1.6)
Vitreous ﬂoaters 1 (0.8) 2 (1.6)
Chalazion 0 (0.0) 2 (1.6)
Treatment-related ocular AEs were those categorized as possibly, probably, or deﬁnitely related to treatment
AE treatment-emergent adverse event, LBN latanoprostene bunod
a Reported as an AE (see Table 2 for investigator assessments of hyperemia)
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large intestine polyp, breast cancer) were
classified after the subject ended study
participation. The serious AE of vestibular
neuronitis was considered severe in intensity,
whereas all other serious AEs were considered
mild or moderate in severity. None of the
serious AEs were considered by the
investigator to be related to study treatment.
No treatment-related changes in blood
pressure or heart rate were observed from
baseline through week 52. Two subjects had
vital sign measurements that were associated
with AEs (mild hypertension) considered to be
not or unlikely related to study drug.
Mean decimal VA at baseline was 1.11 in the
study eye and 1.13 in the treated fellow eye. For
all post-baseline study visits, the mean decimal
VA ranged from 1.10 to 1.13 for the study eye
and 1.10–1.15 for the treated fellow eye.
The incidence of conjunctival hyperemia as
assessed by investigators is summarized in
Table 2 by visit and severity. At baseline, prior
to treatment, mild hyperemia was present in 20
(15.4%) study eyes and 18 (14.3%) treated
fellow eyes. At the week 4 and week 8 visits,
mild hyperemia was noted in additional 6 or 7
eyes in each group. The proportion of eyes with
hyperemia remained low; at the 52 week visit,
Table 2 Incidence of conjunctival hyperemia per investigator assessment, by study visit (safety population treated with LBN
0.024%)
Study visit Any hyperemia/moderate hyperemiaa
Eyes, n (%)
Study eye (N5 130)b Treated fellow eye (N5 126)b
Baseline 20 (15.4)/0 (0.0) 18 (14.3)/0 (0.0)
Week 4 27 (20.8)/0 (0.0) 24 (19.0)/0 (0.0)
Week 8 26 (20.2)/0 (0.0) 24 (19.2)/0 (0.0)
Week 12 24 (18.8)/2 (1.6) 22 (17.7)/2 (1.6)
Week 16 24 (19.0)/1 (0.8) 21 (17.2)/1 (0.8)
Week 20 25 (19.8)/1 (0.8) 22 (18.0)/1 (0.8)
Week 24 25 (19.8)/1 (0.8) 22 (18.0)/1 (0.8)
Week 28 22 (17.5)/1 (0.8) 22 (18.0)/2 (1.6)
Week 32 23 (18.4)/1 (0.8) 22 (18.2)/1 (0.8)
Week 36 22 (17.9)/1 (0.8) 20 (16.8)/1 (0.8)
Week 40 22 (18.0)/1 (0.8) 20 (16.9)/1 (0.8)
Week 44 23 (18.9)/1 (0.8) 20 (16.9)/1 (0.8)
Week 48 22 (18.0)/1 (0.8) 20 (16.9)/1 (0.8)
Week 52 22 (18.2)/1 (0.8) 20 (17.1)/1 (0.9)
LBN latanoprostene bunod
a There were no instances of severe hyperemia in any treated eye during the study
b Data missing for the study eye and the treated fellow eye for one subject at week 8; two subjects at week 12; four subjects
at weeks 16, 20, 24, and 28; ﬁve subjects at week 32; seven subjects at week 36; eight subjects at weeks 40, 44, and 48; and
nine subjects at week 52
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the number of eyes with hyperemia was only 2
higher than at baseline in both the study eye
and treated fellow eye groups. From week 12 on,
there were 1 or 2 eyes in each group with
moderate hyperemia; all other cases were mild.
No subjects had severe conjunctival hyperemia
at any visit during the study.
Abnormal biomicroscopy findings for the lid,
conjunctiva bulbi, the conjunctiva palpebrae,
the cornea, and the anterior chamber were rare
in both study eyes and treated fellow eyes and
showed no consistent patterns. The number of
eyes with abnormal findings for these
assessments either stayed the same or
increased or decreased by 1 or 2 subjects at
each study visit. The number of study and
treated fellow eyes with abnormal iris findings
showed a gradual increase starting at week 20.
Other ocular assessments (anterior chamber
cells, anterior flare, posterior synechiae,
anterior vitreous haze, and number of subjects
with an open or absent posterior lens capsule)
were unremarkable.
Based on the analysis of iris photographs
taken at week 52 in comparison with those
taken at baseline, 10.0% (13/130) of study eyes
and 8.8% of (11/125) of treated fellow eyes were
judged as having a clear iris pigmentation
increase from baseline; and an additional
14.6% (19/130) of study eyes and 13.6% (17/
125) of treated fellow eyes were judged as
having a possible iris pigmentation increase
from baseline.
Ophthalmoscopy findings indicated no
changes in the number of subjects with
abnormalities in the vitreous body, the retina,
the macula, the choroid, the optic nerve, or the
mean cup/disc vertical ratio in the study eye or
the treated fellow eye after 52 weeks of
treatment with LBN 0.024%. At baseline, optic
disc hemorrhage was evident in one study eye
and two treated fellow eyes; at week 4, the
presence of optic disc hemorrhage was
unchanged among study eyes and decreased
by one subject at week 4 in treated fellow eyes.
Missing assessments precluded evaluation of
optic disc hemorrhage at subsequent visits. At
baseline, rim loss was noted in 19 (14.6%) of
study eyes and 13 (10.3%) of treated fellow eyes,
and retinal nerve fiber layer defects were
observed in 13 (10.0%) of study eyes and 6
(4.8%) of treated fellow eyes. There were no
changes in the number of eyes with these
findings at any study visit, and no
notable results from visual field assessment,
gonioscopy, or pachymetry.
Efficacy
The mean (SD) IOP at each visit from baseline to
week 52 for the study eye and the treated fellow
eye for all subjects is shown in Fig. 2, and the
RFB in IOP from baseline to each study visit is
shown in Fig. 3. In the study eye, a 22.0%
reduction in IOP to 15.3 (3.0) mmHg was
achieved by week 4, and reductions greater
than 22% were observed at every subsequent
visit. Similarly, a 19.5% reduction in IOP to 15.0
(2.8) mmHg was achieved by week 4 in the
treated fellow eye, and reductions of more than
20% were seen at every visit after week 4. At
week 52, the percent reductions in IOP were
26.3% and 23.0% in study eyes and treated
fellow eyes, respectively, to 14.4 (2.7) mmHg in
both eyes. For both the study eye and the
treated fellow eye, the reductions from baseline
were statistically significant (P\0.001) at every
study visit from week 4 through week 52.
At weeks 4 and 8, 42.3% and 48.1%,
respectively, of subjects had an RFB in IOP of
C5 mmHg for the study eye. Between 52.3%
and 64.2% of subjects had a reduction in IOP of
C5 mmHg for the study eye from week 12 to
week 52. From weeks 8 to 20, between 42.4%
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and 47.5% of subjects had a reduction in IOP of
C5 mmHg in the treated fellow eye. Reductions
in IOP of C5 mmHg were observed in the
treated fellow eye for 50.0–54.2% of subjects at
weeks 24 and 28 and weeks 36–48, whereas at
week 52, 48.7% of subjects had a reduction in
IOP of C5 mmHg in the treated fellow eye.
DISCUSSION
This multicenter, open-label study in Japanese
subjects with OAG or OHT was designed to
evaluate the long-term safety and IOP-lowering
efficacy of LBN ophthalmic solution 0.24% QD.
The study treatment duration of 12 months is
Fig. 3 Reduction from baseline in mean IOP (mmHg) by visit (safety population). All data points P\0.001 for reduction
from baseline. Standard deviations at each timepoint ranged from 2.61 to 2.88 mmHg. IOP intraocular pressure
Fig. 2 Mean IOP (mmHg) at each study visit in the study
eye and the treated fellow eye (safety population). All
post-baseline measurements P\0.001 vs. baseline.
Standard deviations at each timepoint ranged from 2.31
to 3.00 mmHg. IOP intraocular pressure
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the longest reported with LBN 0.024% to date,
and adds to a growing body of clinical data with
this novel compound [22, 32–35]. Safety was
assessed regularly throughout the study using a
comprehensive battery of prospective ocular
and non-ocular clinical evaluations along with
AE monitoring. The combined findings of the
safety evaluations confirmed the long-term
safety and tolerability of LBN 0.024%. Over
the one-year treatment period, there were no
discontinuations due to AEs. The most common
AEs were cosmetic and typical of topical
prostaglandin analog use [36, 37], including
conjunctival hyperemia and eyelash growth.
Conjunctival hyperemia, mostly mild, was
reported as an AE in 17–18% of treated eyes
and was consistent with the rates of hyperemia
determined by proactive investigator
assessments at each study visit using
photographic standards (range 17–20% of
treated eyes). It should be noted that
investigator-identified hyperemia was present
before treatment initiation in about one of
every six eyes. After the first 4 weeks of LBN
treatment, the prevalence of
investigator-identified hyperemia increased to
1 out of every five eyes, but remained generally
stable, even showing a slight decline over the
remaining 48 weeks. Iris hyperpigmentation is
another well-recognized side effect of topical
prostaglandin analogs [18, 38] with apparently
cosmetic-only implications, based on current
understanding [19, 39]. In the current study, iris
hyperpigmentation was reported as an AE in 4%
of treated eyes, and, at 1 year, an increase in iris
pigmentation was noted in 9% of treated eyes
and a possible increase was noted in another
14% based on iris photographs. Iridial
pigmentation changes have also been reported
with latanoprost in clinical studies with
Japanese subjects [40–43]. These studies found
the incidence of iris pigmentation to increase in
proportion to duration of latanoprost
treatment, with reported frequencies at 1 year
ranging from 51.6% [42] to 58.2% [43] based on
slit-lamp biomicroscopy, a rate much higher
than that found in the current study with LBN.
However, another 1-year study of latanoprost in
124 Japanese patients with primary OAG or
OHT reported iris hyperpigmentation in only
ten patients [44].
Reducing IOP is the primary modifiable
factor in managing patients with, or at risk
for, glaucoma. Expert consensus guidelines
suggest that gold standard pharmacologic
glaucoma therapy is defined by the long-term
control of IOP with no induction of
tachyphylaxis or tolerance [45]. Tachyphylaxis,
or diminished responsiveness to therapy over
time, necessitates therapy modification, often
in the form of adjunctive IOP-lowering agents
[20, 46] which can increase treatment costs and
lessen adherence in some patients [47]. Thus,
the ideal treatment paradigm would be a
monotherapy regimen that is simple to use,
with good tolerability and sustained
IOP-lowering activity over time.
Most long-term, prospective clinical
research studies with prostaglandin analogs
have described effective and sustained
IOP-lowering over multi-year treatment
periods with no apparent tachyphylaxis
[48–52]. However, a number of studies based
on claims data and reflective of ‘‘real world’’
experience suggest that up to one-half of
patients started on prostaglandin analog
monotherapy require adjunctive IOP-lowering
medication within 2 years [20, 53]. It remains
to be investigated whether the dual
mechanism of action of LBN will translate to
practical clinical benefits, including a reduced
need for adjunctive therapy over time, whether
due to sustained efficacy or improved patient
adherence.
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In the current study, significant IOP reduction
with LBN treatment was observed quickly,
evidenced by a mean reduction of 4.3 mmHg or
22%frombaseline in studyeye IOPatweek4.The
IOP-lowering effect was sustained over the entire
52 weeks of the study, and appeared to show a
trend suggestive of continued, progressive
lowering over the 1-year study period. At
52 weeks, the mean reduction in IOP was
5.3 mmHg or greater than 25% from baseline in
the study eye,which correspondswith thedegree
of IOP reduction shown to minimize disease
severity or progression in OAG [5–9].
Garway-Heath et al. [10] recently published
findings from the United Kingdom Glaucoma
Treatment Study (UKGTS; Controlled-trials.com
identifier, ISRCTN96423140) demonstrating not
only IOP lowering, but also clinical benefits in
the form of visual field preservation with the
use of latanoprost therapy compared with
placebo in patients with OAG. Mean IOP
reduction in the UKGTS was 3.8 mmHg in
patients treated with latanoprost, compared
with 0.9 mmHg in the placebo group. In our
study, the mean IOP reduction with LBN
0.024% was typically between 4 and 5 mmHg
at each study visit. Of note, there were also no
apparent visual field changes after 1 year of
treatment with LBN 0.024%, nor were there
any changes in safety parameters that could be
indicative of glaucoma progression (i.e., optic
nerve changes, mean cup/disc vertical ratio,
and rim loss).
Japanese populations are known to have lower
IOPs compared with non-Asian groups, and NTG
is a common finding [54]. The current study
population included subjects with NTG, and the
majority of eyes had a baseline IOP between 15
and 21mmHg. As in high-pressure glaucoma, the
reduction of IOP has been shown to slow visual
field damage in NTG [9, 55] and may minimize
progressionof thedisease [56–58]. A prior studyof
LBN 0.024% in healthy male Japanese volunteers
demonstrated a robust 27% reduction in IOP after
2 weeks of treatment, despite ameanbaseline IOP
of 13.6 mmHg in the study group [32]. Other
prostaglandin analogs have shown IOP-lowering
efficacy in the short-term studies conducted in
subjectswithNTG [59–62]. Further studies of LBN
0.024% in patients with NTG are, therefore,
warranted given the positive findings of the
current study in Japanese subjects. Interestingly,
even though most subjects in the current study
had a baseline IOPB21 mmHg, LBN produced an
IOP reduction similar to that reported in a
previous open-label study of latanoprost 0.005%
in Japanese subjects with OAG or OHT which
excluded subjects with baseline IOP B20 mmHg
and thus had higher baseline IOPs (mean, 23.5
[2.2] mmHg) [44]. The mean (SD) IOP reduction
at week 52 in the latter study was 5.4 (2.9) mmHg
from 23.5 (2.2) mmHg at baseline [44].
Although findings of this study suggest a
promising role for LBN in the long-term
management of patients requiring IOP
reduction, interpretation of the results is
limited by the open-label design and lack of
an active comparator. However, LBN
administered QD in the evening has been
evaluated in two large randomized clinical
studies of primarily non-Asian patients with
OAG or OHT (the APOLLO [33] and LUNAR [35]
studies; ClinicalTrials.gov identifiers,
NCT01749904 and NCT01749930,
respectively) of long duration. Each of these
studies consisted of a 3-month double-masked
efficacy phase in which subjects were
randomized to either LBN QD in the evening
or timolol instilled twice daily followed by an
open-label safety extension phase lasting up to
1 year in which all subjects received LBN
0.024%. In both studies, LBN was associated
with significantly greater diurnal IOP
reductions compared with timolol over the
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3-months of double-masked treatment [33, 35].
Furthermore, the IOP lowering with LBN was
maintained through the open-label phase of
these studies [63].
CONCLUSION
The results of this single-arm, multicenter,
open-label, clinical study suggest that LBN
ophthalmic solution 0.024% QD was safe and
well-tolerated, with no significant AEs in
Japanese subjects when used for up to 1 year.
In addition, the results demonstrated that the
long-term treatment with LBN ophthalmic
solution 0.024% provided significant and
sustained reduction of IOP in Japanese subjects
with a diagnosis of OAG or OHT.
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